Axithra develops a platform utilizing proprietary optical and photonics technology to rapidly and accurately measure drug concentrations in blood, enabling personalized treatment plans for patients. The initial focus is on optimizing beta-lactam antibiotic therapies in intensive care units, enhancing drug effectiveness and minimizing adverse reactions.
Funding
$10.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for measuring drug concentrations in blood are often slow and lack the ability to provide real-time, personalized treatment adjustments. This can lead to suboptimal drug effectiveness and increased risk of adverse reactions, particularly in critical care settings.
Solution
Axithra is developing a platform that leverages proprietary optical and photonics technology to enable rapid and accurate measurement of drug concentrations in blood at the point of need. This technology aims to provide clinicians with clinically actionable results tailored to individual patients, facilitating personalized treatment plans. By optimizing drug effectiveness and minimizing adverse drug reactions, Axithra's platform seeks to improve patient outcomes and contribute to advantageous health economics, initially focusing on beta-lactam antibiotics in intensive care units.
Target Audience
The primary target audience includes physicians and healthcare providers in intensive care units who require rapid and accurate drug monitoring for personalized treatment plans.
Features
- Proprietary optical and photonics technology for rapid drug concentration measurement
- Point-of-need testing capabilities for real-time treatment adjustments
- Personalized treatment plans based on individual patient needs
- Focus on optimizing beta-lactam antibiotic therapies in intensive care units